Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pharma-Bio Serv (PBSV) Net Margin (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed Net Margin for 15 consecutive years, with 0.0% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin fell 70.0% year-over-year to 0.0%, compared with a TTM value of 4.49% through Oct 2025, up 368.0%, and an annual FY2025 reading of 1.12%, up 706.0% over the prior year.
  • Net Margin was 0.0% for Q4 2025 at Pharma-Bio Serv, up from 15.75% in the prior quarter.
  • Across five years, Net Margin topped out at 11.5% in Q3 2023 and bottomed at 87.05% in Q4 2021.
  • Average Net Margin over 5 years is 3.6%, with a median of 2.73% recorded in 2021.
  • The sharpest move saw Net Margin crashed -8993bps in 2021, then skyrocketed 9204bps in 2022.
  • Year by year, Net Margin stood at 87.05% in 2021, then skyrocketed by 106bps to 4.98% in 2022, then tumbled by -126bps to 1.31% in 2023, then soared by 153bps to 0.69% in 2024, then plummeted by -101bps to 0.0% in 2025.
  • Business Quant data shows Net Margin for PBSV at 0.0% in Q4 2025, 15.75% in Q3 2025, and 4.3% in Q2 2025.